MX9709468A - Composiciones farmaceuticas para minimizar la perdida osea. - Google Patents
Composiciones farmaceuticas para minimizar la perdida osea.Info
- Publication number
- MX9709468A MX9709468A MX9709468A MX9709468A MX9709468A MX 9709468 A MX9709468 A MX 9709468A MX 9709468 A MX9709468 A MX 9709468A MX 9709468 A MX9709468 A MX 9709468A MX 9709468 A MX9709468 A MX 9709468A
- Authority
- MX
- Mexico
- Prior art keywords
- calcium channel
- channel antagonists
- pharmaceutically
- alkyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invencion proporciona un método para minimizar el efecto de la pérdida osea de un compuesto de la formula (II) o una sal farmacéuticamente aceptable del mismo, en donde el compuesto de la formula (II) es administrado a un mamífero en necesidad de tratamiento, que comprende la administracion concurrente o secuencial al mamífero, de una cantidad efectiva de un compuesto de la formula (I), en donde cada R1 es independientemente -H, -OH, -O(alquilo de 1 a 4 átomos de carbono), -OCOC6H5, OCO(alquilo de 1 a 6 átomos de carbono), o - OSO2(alquilo de 4 a 6 átomos de carbono); y R2 es 1-piperidinilo, 1-pirrolidinilo, 4-morfolino, dimetilamino, dietilamino, o 1-hexametilenimino; o una sal farmacéuticamente aceptable del mismo. También se proporciona el método para minimizar la pérdidaosea inducida por la administracion de un compuesto de la formula (II), que comprende el administrar concurrentemente o secuencialmente un agente anabolicooseo. Se proporcionan también las composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/485,406 US5840747A (en) | 1995-06-07 | 1995-06-07 | Calcium channel antagonists |
PCT/US1996/009162 WO1996040134A1 (en) | 1995-06-07 | 1996-06-04 | Calcium channel antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9709468A true MX9709468A (es) | 1998-04-30 |
Family
ID=23928032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9709468A MX9709468A (es) | 1995-06-07 | 1996-06-04 | Composiciones farmaceuticas para minimizar la perdida osea. |
Country Status (21)
Country | Link |
---|---|
US (1) | US5840747A (es) |
EP (1) | EP0831822B1 (es) |
JP (1) | JPH11506788A (es) |
KR (1) | KR19990022499A (es) |
CN (1) | CN1193274A (es) |
AT (1) | ATE252902T1 (es) |
AU (1) | AU714403B2 (es) |
CA (1) | CA2223711A1 (es) |
CZ (1) | CZ288546B6 (es) |
DE (1) | DE69630523T2 (es) |
EA (1) | EA001928B1 (es) |
ES (1) | ES2210373T3 (es) |
HU (1) | HUP9900916A3 (es) |
IL (1) | IL122459A (es) |
MX (1) | MX9709468A (es) |
NO (1) | NO975561L (es) |
NZ (1) | NZ310178A (es) |
PL (1) | PL183998B1 (es) |
RO (1) | RO116344B1 (es) |
UA (1) | UA43895C2 (es) |
WO (1) | WO1996040134A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
WO2001026651A2 (en) * | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US5447941A (en) * | 1993-12-21 | 1995-09-05 | Eli Lilly And Company | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
US5441965A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5532254A (en) * | 1995-06-07 | 1996-07-02 | Eli Lilly And Company | Modulation of calcium channels using benzothiophenes |
-
1995
- 1995-06-07 US US08/485,406 patent/US5840747A/en not_active Expired - Fee Related
-
1996
- 1996-04-06 UA UA97125831A patent/UA43895C2/uk unknown
- 1996-06-04 NZ NZ310178A patent/NZ310178A/en unknown
- 1996-06-04 HU HU9900916A patent/HUP9900916A3/hu unknown
- 1996-06-04 ES ES96918210T patent/ES2210373T3/es not_active Expired - Lifetime
- 1996-06-04 CN CN96195976A patent/CN1193274A/zh active Pending
- 1996-06-04 AT AT96918210T patent/ATE252902T1/de not_active IP Right Cessation
- 1996-06-04 EA EA199800033A patent/EA001928B1/ru not_active IP Right Cessation
- 1996-06-04 RO RO97-02247A patent/RO116344B1/ro unknown
- 1996-06-04 AU AU60919/96A patent/AU714403B2/en not_active Ceased
- 1996-06-04 CA CA002223711A patent/CA2223711A1/en not_active Abandoned
- 1996-06-04 PL PL96324086A patent/PL183998B1/pl unknown
- 1996-06-04 EP EP96918210A patent/EP0831822B1/en not_active Expired - Lifetime
- 1996-06-04 IL IL12245996A patent/IL122459A/en not_active IP Right Cessation
- 1996-06-04 MX MX9709468A patent/MX9709468A/es not_active IP Right Cessation
- 1996-06-04 JP JP9501551A patent/JPH11506788A/ja active Pending
- 1996-06-04 CZ CZ19973828A patent/CZ288546B6/cs not_active IP Right Cessation
- 1996-06-04 DE DE69630523T patent/DE69630523T2/de not_active Expired - Fee Related
- 1996-06-04 WO PCT/US1996/009162 patent/WO1996040134A1/en not_active Application Discontinuation
- 1996-06-04 KR KR1019970708980A patent/KR19990022499A/ko not_active Application Discontinuation
-
1997
- 1997-12-02 NO NO975561A patent/NO975561L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO975561D0 (no) | 1997-12-02 |
CA2223711A1 (en) | 1996-12-19 |
HUP9900916A2 (hu) | 1999-09-28 |
CZ288546B6 (cs) | 2001-07-11 |
CZ382897A3 (cs) | 1999-01-13 |
EP0831822A1 (en) | 1998-04-01 |
EP0831822B1 (en) | 2003-10-29 |
IL122459A0 (en) | 1998-06-15 |
IL122459A (en) | 2001-05-20 |
WO1996040134A1 (en) | 1996-12-19 |
DE69630523D1 (de) | 2003-12-04 |
UA43895C2 (uk) | 2002-01-15 |
CN1193274A (zh) | 1998-09-16 |
DE69630523T2 (de) | 2004-08-12 |
US5840747A (en) | 1998-11-24 |
KR19990022499A (ko) | 1999-03-25 |
JPH11506788A (ja) | 1999-06-15 |
NO975561L (no) | 1997-12-02 |
PL183998B1 (pl) | 2002-08-30 |
RO116344B1 (ro) | 2001-01-30 |
EA001928B1 (ru) | 2001-10-22 |
EA199800033A1 (ru) | 1998-06-25 |
ATE252902T1 (de) | 2003-11-15 |
ES2210373T3 (es) | 2004-07-01 |
AU714403B2 (en) | 2000-01-06 |
EP0831822A4 (en) | 2001-12-19 |
NZ310178A (en) | 2000-06-23 |
PL324086A1 (en) | 1998-05-11 |
AU6091996A (en) | 1996-12-30 |
HUP9900916A3 (en) | 1999-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY132251A (en) | Methods of inhibiting cell-cell adhesion | |
BG105271A (en) | 1h-imidazopyridine derivatives | |
MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
MX9701329A (es) | Metodos para la inhibicion de la replicacion viral. | |
AU8156194A (en) | Methods of inhibiting dysfunctional uterine bleeding | |
IL122282A0 (en) | Modulation of calcium channels | |
MX9709466A (es) | Medicamento para inhibir el melanoma. | |
EA199700136A1 (ru) | Способы ингибирования экзогенных эстрогенов | |
MX9709468A (es) | Composiciones farmaceuticas para minimizar la perdida osea. | |
MX9702148A (es) | Metodos para inhibir la mitosis endometrial. | |
MX9701327A (es) | Metodos para inhibir el cancer endometrial. | |
MX9709542A (es) | Modulacion de los canales de calcio. | |
MX9701359A (es) | Metodos para la inhibicion de la hiperplasia endometrial primaria. | |
MX9705215A (es) | Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento. | |
MX9701331A (es) | Metodos para mantener los dientes y los huesos bucales. | |
MX9705940A (es) | Metodos y composiciones para inhibir los efectos de la interleucina 6. | |
MX9705697A (es) | Metodos para reducir los niveles de calcio del suero. | |
MX9701328A (es) | Metodos de reduccion de la cicatrizacion en la curacion de heridas. | |
MX9702861A (es) | Metodo para inhibir las condiciones asociadas con la bradicinina. | |
MX9706520A (es) | Metodos para inhibir el cancer de ovario. | |
MX9702853A (es) | Metodos para inhibir condiciones asociadas con el neuropeptido "y". |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |